TheraRadar
← Back
Data updated: Mar 29, 2026

ARGENX BV

NeurologyOphthalmologyMetabolic
Biotech

ARGENX BV is a biotechnology company focused on Neurology, Ophthalmology, Metabolic. Key products include VYVGART.

2021
Since
2
Drugs
-
Trials
8
Approved (2yr)

Key Drugs

VYVGART
efgartigimod alfa
FcRn 1 indications · 2021

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

VYVGART 2025-10-17
Efficacy
VYVGART HYTRULO 2025-10-17
Efficacy
VYVGART HYTRULO 2025-04-10
Efficacy
VYVGART 2024-08-08
Efficacy
VYVGART HYTRULO 2024-08-08
Efficacy
VYVGART 2024-07-24
Labeling
VYVGART HYTRULO 2024-06-21
Efficacy
VYVGART HYTRULO 2024-06-21
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Neurology 54%
1 drugs Phase 3: 3 Phase 2: 4 Phase 1: 1
Ophthalmology 24%
0 drugs Phase 3: 3
Metabolic 16%
0 drugs Phase 3: 2
Immunology 4%
0 drugs Phase 2: 1
Oncology 2%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

AbbVie big-pharma
Immunology, Oncology, Neurology, Ophthalmology
Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Neurology
Roche big-pharma
Oncology, Neurology, Ophthalmology, Immunology
Takeda big-pharma
Immunology, Oncology, Neurology, Metabolic
Novartis big-pharma
Oncology, Immunology, Ophthalmology